Amylyx Pharmaceuticals (NASDAQ:AMLX) Releases Quarterly Earnings Results, Meets Estimates

Amylyx Pharmaceuticals (NASDAQ:AMLX) posted its quarterly earnings data on Thursday. The company reported ($0.38) EPS for the quarter, meeting analysts’ consensus estimates of ($0.38), FiscalAI reports.

Here are the key takeaways from Amylyx Pharmaceuticals’ conference call:

• Avexitide’s Phase III LUCIDITY trial met its primary and all secondary endpoints, including a 55% reduction in the composite rate of level 2 and level 3 hypoglycemic events versus placebo, with a favorable safety profile. Amylyx remains on track to submit an NDA by year-end and is preparing for a potential 2027 launch, subject to FDA review.
• An oversubscribed equity offering generated $545 million in net proceeds, bringing cash and cash equivalents to $768 million at quarter-end. Management said the funds support NDA preparation, launch readiness, and pipeline development.
• The company estimates about 160,000 people in the U.S. live with PBH and reports growing physician interest in treatment options; a PBH-specific ICD-10 code took effect in October. These market-size and demand assessments are based on Amylyx’s analyses and research.
• Operating expenses rose 38% year over year to $49.7 million, reflecting higher trial spending and pre-commercialization costs; stock-based compensation also increased. The higher spending comes as Amylyx scales its commercial organization ahead of a possible launch.
• Beyond avexitide, Amylyx is targeting a 2027 IND filing for AMX0318, while its AMX0114 ALS trial has advanced to enrollment in its fourth dose cohort. The company also reported progress on a research collaboration, but did not provide new efficacy results for these programs.

Amylyx Pharmaceuticals Price Performance

Shares of Amylyx Pharmaceuticals stock opened at $29.50 on Friday. The company’s 50 day moving average price is $30.00 and its two-hundred day moving average price is $20.41. Amylyx Pharmaceuticals has a fifty-two week low of $10.83 and a fifty-two week high of $41.14. The firm has a market capitalization of $3.29 billion, a P/E ratio of -20.49 and a beta of -0.09.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other news, Director George M. Milne, Jr. sold 30,000 shares of the business’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $27.70, for a total value of $831,000.00. Following the completion of the sale, the director owned 782,881 shares of the company’s stock, valued at approximately $21,685,803.70. The trade was a 3.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Gina Mazzariello sold 9,536 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $32.46, for a total transaction of $309,538.56. Following the transaction, the insider owned 190,838 shares of the company’s stock, valued at $6,194,601.48. The trade was a 4.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 60,374 shares of company stock worth $1,815,257. 10.90% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages recently weighed in on AMLX. Citigroup lifted their price objective on shares of Amylyx Pharmaceuticals from $32.00 to $39.00 and gave the company a “buy” rating in a research report on Thursday, October 15th. Wolfe Research raised Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 17th. Mizuho raised their price target on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an “outperform” rating in a research report on Tuesday, August 18th. Stifel Nicolaus set a $45.00 target price on Amylyx Pharmaceuticals in a research report on Thursday. Finally, Robert W. Baird raised their price objective on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an “outperform” rating in a research report on Wednesday, August 19th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $44.14.

Key Amylyx Pharmaceuticals News

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $55 price target, while forecasting quarterly losses to narrow from $0.38 per share in Q1 2027 to $0.32 in Q4 2027. The rating and target may support investor optimism. Analyst estimates and rating
• Neutral Sentiment: Amylyx reported a Q3 2026 loss of $0.38 per share, matching the consensus estimate. The in-line result was not a positive earnings surprise. Third-quarter financial results
• Neutral Sentiment: The company’s Q3 2026 earnings-call transcript was published, but the provided coverage does not detail additional announcements or outlook changes from the call. Q3 2026 earnings-call transcript

About Amylyx Pharmaceuticals